Interpace Diagnostics Group (NASDAQ:IDXG) Shares Down 10.8%
Shares of Interpace Diagnostics Group Inc (NASDAQ:IDXG) dropped 10.8% on Tuesday . The stock traded as low as $0.72 and last traded at $0.74, approximately 916,334 shares traded hands during mid-day trading. An increase of 229% from the average daily volume of 278,670 shares. The stock had previously closed at $0.83.
Separately, HC Wainwright set a $2.00 target price on Interpace Diagnostics Group and gave the company a “buy” rating in a report on Friday, July 19th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Interpace Diagnostics Group presently has an average rating of “Buy” and a consensus price target of $2.81.
The company has a market capitalization of $28.26 million, a price-to-earnings ratio of -1.72 and a beta of 2.17. The firm’s fifty day moving average price is $0.80. The company has a current ratio of 2.26, a quick ratio of 2.26 and a debt-to-equity ratio of 0.05.
An institutional investor recently raised its position in Interpace Diagnostics Group stock. Stonepine Capital Management LLC boosted its position in Interpace Diagnostics Group Inc (NASDAQ:IDXG) by 22.3% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,753,184 shares of the business services provider’s stock after buying an additional 319,154 shares during the quarter. Interpace Diagnostics Group accounts for approximately 0.9% of Stonepine Capital Management LLC’s holdings, making the stock its 21st biggest holding. Stonepine Capital Management LLC owned about 4.59% of Interpace Diagnostics Group worth $1,271,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 22.80% of the company’s stock.
Interpace Diagnostics Group Company Profile (NASDAQ:IDXG)
Interpace Diagnostics Group, Inc develops and commercializes molecular diagnostic tests to detect genetic and other molecular alterations associated with gastrointestinal and endocrine cancers. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test that helps physicians better assess risk of pancreaticobiliary cancers using its proprietary PathFinder platform; ThyGenX, an oncogenic mutation panel that helps identify malignant thyroid nodules; and ThyraMIR, an microRNA gene expression assay that helps to classify risk of cancer in thyroid nodules.
Receive News & Ratings for Interpace Diagnostics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Interpace Diagnostics Group and related companies with MarketBeat.com's FREE daily email newsletter.